HIV integrase inhibitors

US8039458B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• B. Narasimhulu Naidu · Durham, US
• Yasutsugu Ueda · Clinton, US
• John D. Matiskella · Wallingford, US
• Michael A. Walker · Durham, US
• Jacques Banville · St-Hubert, CA
• Francis Beaulieu · Elliot Lake, CA
• Carl Ouellet · Boucherville, CA
• Serge Plamondon · Russell, CA

Key dates

• Filing date: Oct 31, 2006
• Grant date: Oct 18, 2011
• Expiry date: Jan 26, 2029

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D498/20
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The invention encompasses a series bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.